GO
Loading...

Bristol-Myers Squibb Co

More

  • Early Glance: Pharmaceuticals companies Thursday, 11 Dec 2014 | 11:28 AM ET

    Baxter International Inc. rose$. 59 or. 8 percent, to $73.35. Bristol-Myers Squibb Co. rose$. 71 or 1.2 percent, to $59.99. Hospira rose $2.35 or 4.0 percent, to $61.74.

  • Final Glance: Pharmaceuticals companies Wednesday, 10 Dec 2014 | 6:09 PM ET

    Baxter International Inc. fell $1.03 or 1.4 percent, to $72.76. Bristol-Myers Squibb Co. fell$. 69 or 1.2 percent, to $59.28. Hospira fell$. 97 or 1.6 percent, to $59.39.

  • Midday Glance: Pharmaceuticals companies Wednesday, 10 Dec 2014 | 1:18 PM ET

    Baxter International Inc. fell$. 39 or. 5 percent, to $73.40. Bristol-Myers Squibb Co. rose$. 06 or. 1 percent, to $60.03. Hospira fell$. 11 or. 2 percent, to $60.25.

  • Early Glance: Pharmaceuticals companies Wednesday, 10 Dec 2014 | 10:41 AM ET

    Baxter International Inc. fell$. 08 or. 1 percent, to $73.71. Hospira fell$. 56 or. 9 percent, to $59.80. Eli Lilly& Co. fell$. 56 or. 8 percent, to $71.65.

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Final Glance: Pharmaceuticals companies Tuesday, 9 Dec 2014 | 6:10 PM ET

    Baxter International Inc. fell$. 33 or. 4 percent, to $73.79. Bristol-Myers Squibb Co. fell$. 70 or 1.2 percent, to $59.97. Hospira rose$. 24 or. 4 percent, to $60.36.

  • Midday Glance: Pharmaceuticals companies Tuesday, 9 Dec 2014 | 1:21 PM ET

    Baxter International Inc. fell$. 74 or 1.0 percent, to $73.38. Bristol-Myers Squibb Co. fell$. 92 or 1.5 percent, to $59.75. Hospira fell$. 11 or. 2 percent, to $60.01.

  • Early Glance: Pharmaceuticals companies Tuesday, 9 Dec 2014 | 10:21 AM ET

    Baxter International Inc. fell$. 61 or. 8 percent, to $73.51. Bristol-Myers Squibb Co. fell$. 87 or 1.4 percent, to $59.80. Hospira rose$. 74 or 1.2 percent, to $60.86.

  • Final Glance: Pharmaceuticals companies Monday, 8 Dec 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 10 or. 1 percent, to $74.12. Bristol-Myers Squibb Co. rose$. 02 or percent, to $60.67. Hospira rose$. 02 or percent, to $60.12.

  • NEW YORK, Dec 8- The U.S. government on Monday sued Deutsche Bank AG, seeking to recoup more than $190 million from the German bank over alleged tax fraud more than 14 years ago. According to a complaint filed in the U.S. District Court in Manhattan, Deutsche Bank used "insolvent" shell companies to conduct a series of fraudulent conveyances designed to hide taxable...

  • McDonald's and Sony are big market movers Monday, 8 Dec 2014 | 4:41 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. McDonald's Corp., down $3.70 to $92.61. Sony Corp., down $1.01 to $21.15.

  • Midday Glance: Pharmaceuticals companies Monday, 8 Dec 2014 | 1:20 PM ET

    Baxter International Inc. fell$. 01 or percent, to $74.21. Bristol-Myers Squibb Co. rose$. 18 or. 3 percent, to $60.83. Hospira fell$. 09 or. 1 percent, to $60.01.

  • Early Glance: Pharmaceuticals companies Monday, 8 Dec 2014 | 10:22 AM ET

    Baxter International Inc. rose$. 13 or. 2 percent, to $74.35. Bristol-Myers Squibb Co. rose$. 13 or. 2 percent, to $60.78. Hospira fell$. 22 or. 4 percent, to $59.88.

  • Dec 6- Merck& Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting. Craig Moskowitz, the study's principal investigator from Memorial Sloan Kettering Cancer...

  • Dec 6- Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday. Margaret Shipp, co-lead investigator of the Checkmate-039 study from Dana-Farber Cancer Institute in Boston. The results were being...

  • Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York- based company's experimental medicines. But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential...

  • FDA declines to approve Bristol-Myers hepatitis drug Wednesday, 26 Nov 2014 | 11:56 AM ET

    Nov 26- Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs.

  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.

  • BUSINESS-NEWS-SCHEDULE AT 2200 GMT / 5 PM ET Sunday, 16 Nov 2014 | 4:46 PM ET

    WASHINGTON- President Barack Obama defends the transparency of his signature healthcare law after a White House adviser on the reform said the law passed, in part, because of the "stupidity" of American voters. ALLERGAN, ACTAVIS NEAR DEAL, ANNOUNCEMENT AS EARLY AS MONDAY. NEW YORK- Allergan nears a deal to merge with Actavis Plc, with an announcement coming as soon as...

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...